BREAKING NEWS

BREAKING NEWS

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Now Reading:

Pfizer, Astellas revise two cancer drug trial protocols to speed up results

Pfizer, Astellas revise two cancer drug trial protocols to speed up results
@ Copyright :
Andrew Kelly(Reuters)
Text size Aa Aa

(Reuters) - Drugmakers Pfizer Inc <PFE.N> and Astellas Pharma Inc <4503.T> said on Wednesday they would change protocols for two late-stage trials testing prostate cancer drug Xtandi to speed up completion.

The companies now expect the ARCHES trial to end late this year, ahead of the previously anticipated completion date of April 2020, and the EMBARK trial to complete by mid-2020, earlier than the prior goal of March 2021.

Both trials are testing Xtandi in men with hormone-sensitive prostate cancer.

Xtandi is already approved in the United States to treat castration-resistant prostate cancer and brought Pfizer revenue of $171 million in the latest reported quarter.

Prostate cancer is the second most common cancer in men worldwide and over 164,000 men in the United States are estimated to be newly diagnosed with the disease this year, according to the American Cancer Society.

(Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.